<p>根据最近向证券交易委员会的披露，Principal Financial Group Inc. 在第三季度将其在 Dynavax Technologies Corporation（纳斯达克代码：DVAX - 免费报告）中的持股比例降低了 12.9%。该机构投资者在季度内出售了 71,315 股后，持有 482,247 股该生物制药公司的股票。Principal Financial Group Inc. 在最近一个季度末持有 Dynavax Technologies 的 0.41%，价值 4,789,000 美元。</p>
<p>其他一些对冲基金最近也买卖了 DVAX 的股票。Osaic Holdings Inc. 在第二季度将其在 Dynavax Technologies 的持股提高了 15.1%。Osaic Holdings Inc. 目前持有 9,336 股该生物制药公司的股票，价值 93,000 美元，此前在上个季度额外购买了 1,226 股。Summit Global Investments 在第三季度收购了 Dynavax Technologies 的新股份，价值约 113,000 美元。Catalyst Funds Management Pty Ltd 在第二季度购买了 Dynavax Technologies 的新股份，价值约 121,000 美元。VIRGINIA RETIREMENT SYSTEMS ET Al 在第三季度收购了 Dynavax Technologies 的新职位，价值约 122,000 美元。最后，Pinnacle Wealth Planning Services Inc. 在第二季度购买了 Dynavax Technologies 的新职位，价值 127,000 美元。96.96% 的股票由机构投资者和对冲基金持有。</p>
<p>获取 <strong>Dynavax Technologies</strong> 警报：</p>
<h2>Dynavax Technologies 股票表现</h2>
<p>Dynavax Technologies 的股票周一开盘价为 15.50 美元。该股票的市值为 18.2 亿美元，市盈率为-41.89，贝塔值为 0.97。该公司的 50 日简单移动平均为 14.40 美元，200 日简单移动平均为 11.82 美元。公司快速比率为 6.94，流动比率为 7.62，债务与股本比率为 0.41。Dynavax Technologies Corporation 的 12 个月低点为 9.20 美元，12 个月高点为 15.73 美元。</p>
<h2>Dynavax Technologies 内部活动</h2>
<p>在其他 Dynavax Technologies 的新闻中，首席运营官 David F. Novack 在 1 月 15 日星期四出售了 114,000 股公司的股票。股票以平均价格 15.64 美元出售，总价值为 1,782,960.00 美元。交易后，首席运营官持有 63,344 股公司股票，价值约 990,700.16 美元。这代表其持股比例下降了 64.28%。该交易已在向证券交易委员会的备案中披露，相关信息可通过 SEC 网站获取。公司内部人士持有公司股票的 2.98%。</p>
<h2>华尔街分析师预测增长</h2>
<p>一些券商最近对 DVAX 发表了评论。Weiss Ratings 在 1 月 21 日星期三的研究报告中重申了对 Dynavax Technologies 股票的 “卖出（d）” 评级。Wall Street Zen 在周六的报告中将 Dynavax Technologies 的评级提升至 “强力买入”。最后，William Blair 在 12 月 24 日星期三的研究报告中将 Dynavax Technologies 的评级从 “跑赢大盘” 下调至 “持有”。两位股票研究分析师给予该股票买入评级，一位给予持有评级，两位给予卖出评级。根据 MarketBeat.com 的数据，该股票的共识评级为 “持有”，共识目标价为 24.33 美元。</p>
<p><strong>阅读我们关于 DVAX 的最新研究报告</strong></p>
<h2>关于 Dynavax Technologies</h2>
<p>（免费报告）</p>
<p>Dynavax Technologies Corporation 是一家生物制药公司，专注于新型疫苗和免疫疗法的开发和商业化。公司总部位于加利福尼亚州埃默里维尔，专注于利用其专有的类 Toll 样受体（TLR）激动剂平台来增强免疫反应。其主要产品 HEPLISAV-B 是一种两剂量的乙型肝炎疫苗，已获得美国食品和药物管理局的批准，结合了 CpG 1018 佐剂，以刺激成人快速而强烈的抗体反应。</p>
<p>Dynavax 成立于 1993 年，已建立起一个超越乙型肝炎的产品管道，包括针对季节性流感、呼吸道合胞病毒（RSV）和新兴传染病的候选药物。</p>
<h2>特色文章</h2>
<ul>
<li>五只我们更看好的股票，胜过 Dynavax Technologies</li>
<li>这只 15 美元的股票可能会成为 2026 年的第一只股票</li>
<li>我 70 岁，拥有 150 万美元：将每年 12 万美元转换为罗斯 IRA 是否明智，还是代价高昂的错误？（咨询顾问）</li>
<li>紧急：立即出售这只股票</li>
<li>他们刚刚试图打击黄金</li>
<li>你的银行账户不再安全</li>
</ul>
<p><strong>想看看其他对冲基金持有的 DVAX 吗？</strong> 访问 HoldingsChannel.com，获取 Dynavax Technologies Corporation（纳斯达克代码：DVAX - 免费报告）的最新 13F 备案和内部交易信息。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RFZBWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RFZBWA"/></p>
<p><em>此即时新闻警报由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Dynavax Technologies 吗？</h2>
<p>在考虑 Dynavax Technologies 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而 Dynavax Technologies 并不在名单上。</p>
<p>虽然 Dynavax Technologies 目前在分析师中获得了持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

医药突破 ETF - ALPS

IBBQ

纳斯达克生物科技指数 ETF - iShares Nasdaq

德纳维制药

生物科技 ETF - VanEck Vectors

标普生物技术 ETF - SPDR

纽交所高增长板生物技术指数 ETF - First Trust

<p>Principal Financial Group Inc. 在第三季度减少了对 Dynavax Technologies Corporation (NASDAQ:DVAX) 的持股比例，下降了 12.9%，目前持有 482,247 股，价值 479 万美元。其他对冲基金也调整了他们的持仓。该股票开盘价为 15.50 美元，市值为 18.2 亿美元。分析师对 DVAX 的评级褒贬不一，普遍评级为 “持有”，目标价为 24.33 美元。Dynavax 专注于开发疫苗和免疫疗法，包括其获得 FDA 批准的乙型肝炎疫苗 HEPLISAV-B</p>

<p>Principal Financial Group Inc. lowered its position in shares of Dynavax Technologies Corporation (NASDAQ:DVAX - Free Report) by 12.9% in the 3rd quarter, according to its most recent disclosure with the Securities &amp; Exchange Commission. The institutional investor owned 482,247 shares of the biopharmaceutical company's stock after selling 71,315 shares during the quarter. Principal Financial Group Inc. owned 0.41% of Dynavax Technologies worth $4,789,000 at the end of the most recent quarter.</p>
<div class="lb-trans"><p>根据最近向证券交易委员会的披露，Principal Financial Group Inc. 在第三季度将其在 Dynavax Technologies Corporation（纳斯达克代码：DVAX - 免费报告）中的持股比例降低了 12.9%。该机构投资者在季度内出售了 71,315 股后，持有 482,247 股该生物制药公司的股票。Principal Financial Group Inc. 在最近一个季度末持有 Dynavax Technologies 的 0.41%，价值 4,789,000 美元。</p>
</div><p>A number of other hedge funds have also recently bought and sold shares of DVAX. Osaic Holdings Inc. lifted its holdings in Dynavax Technologies by 15.1% in the 2nd quarter. Osaic Holdings Inc. now owns 9,336 shares of the biopharmaceutical company's stock valued at $93,000 after acquiring an additional 1,226 shares during the last quarter. Summit Global Investments acquired a new stake in Dynavax Technologies during the third quarter valued at approximately $113,000. Catalyst Funds Management Pty Ltd bought a new stake in Dynavax Technologies during the second quarter worth approximately $121,000. VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new position in Dynavax Technologies in the third quarter worth approximately $122,000. Finally, Pinnacle Wealth Planning Services Inc. bought a new position in shares of Dynavax Technologies in the second quarter valued at $127,000. 96.96% of the stock is owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>其他一些对冲基金最近也买卖了 DVAX 的股票。Osaic Holdings Inc. 在第二季度将其在 Dynavax Technologies 的持股提高了 15.1%。Osaic Holdings Inc. 目前持有 9,336 股该生物制药公司的股票，价值 93,000 美元，此前在上个季度额外购买了 1,226 股。Summit Global Investments 在第三季度收购了 Dynavax Technologies 的新股份，价值约 113,000 美元。Catalyst Funds Management Pty Ltd 在第二季度购买了 Dynavax Technologies 的新股份，价值约 121,000 美元。VIRGINIA RETIREMENT SYSTEMS ET Al 在第三季度收购了 Dynavax Technologies 的新职位，价值约 122,000 美元。最后，Pinnacle Wealth Planning Services Inc. 在第二季度购买了 Dynavax Technologies 的新职位，价值 127,000 美元。96.96% 的股票由机构投资者和对冲基金持有。</p>
</div><p>Get <strong>Dynavax Technologies</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Dynavax Technologies</strong> 警报：</p>
</div><h2>Dynavax Technologies Stock Performance</h2>
<div class="lb-trans"><h2>Dynavax Technologies 股票表现</h2>
</div><p>Shares of Dynavax Technologies stock opened at $15.50 on Monday. The stock has a market cap of $1.82 billion, a PE ratio of -41.89 and a beta of 0.97. The business has a fifty day simple moving average of $14.40 and a 200-day simple moving average of $11.82. The company has a quick ratio of 6.94, a current ratio of 7.62 and a debt-to-equity ratio of 0.41. Dynavax Technologies Corporation has a 12 month low of $9.20 and a 12 month high of $15.73.</p>
<div class="lb-trans"><p>Dynavax Technologies 的股票周一开盘价为 15.50 美元。该股票的市值为 18.2 亿美元，市盈率为-41.89，贝塔值为 0.97。该公司的 50 日简单移动平均为 14.40 美元，200 日简单移动平均为 11.82 美元。公司快速比率为 6.94，流动比率为 7.62，债务与股本比率为 0.41。Dynavax Technologies Corporation 的 12 个月低点为 9.20 美元，12 个月高点为 15.73 美元。</p>
</div><h2>Insider Activity at Dynavax Technologies</h2>
<div class="lb-trans"><h2>Dynavax Technologies 内部活动</h2>
</div><p>In other Dynavax Technologies news, COO David F. Novack sold 114,000 shares of the company's stock in a transaction that occurred on Thursday, January 15th. The shares were sold at an average price of $15.64, for a total value of $1,782,960.00. Following the transaction, the chief operating officer owned 63,344 shares in the company, valued at approximately $990,700.16. This represents a 64.28% decrease in their position. The transaction was disclosed in a filing with the Securities &amp; Exchange Commission, which is available through the SEC website. Corporate insiders own 2.98% of the company's stock.</p>
<div class="lb-trans"><p>在其他 Dynavax Technologies 的新闻中，首席运营官 David F. Novack 在 1 月 15 日星期四出售了 114,000 股公司的股票。股票以平均价格 15.64 美元出售，总价值为 1,782,960.00 美元。交易后，首席运营官持有 63,344 股公司股票，价值约 990,700.16 美元。这代表其持股比例下降了 64.28%。该交易已在向证券交易委员会的备案中披露，相关信息可通过 SEC 网站获取。公司内部人士持有公司股票的 2.98%。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>华尔街分析师预测增长</h2>
</div><p>A number of brokerages have recently commented on DVAX. Weiss Ratings reiterated a &#34;sell (d)&#34; rating on shares of Dynavax Technologies in a research report on Wednesday, January 21st. Wall Street Zen raised Dynavax Technologies to a &#34;strong-buy&#34; rating in a report on Saturday. Finally, William Blair cut Dynavax Technologies from an &#34;outperform&#34; rating to a &#34;hold&#34; rating in a research note on Wednesday, December 24th. Two equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of &#34;Hold&#34; and a consensus price target of $24.33.</p>
<div class="lb-trans"><p>一些券商最近对 DVAX 发表了评论。Weiss Ratings 在 1 月 21 日星期三的研究报告中重申了对 Dynavax Technologies 股票的 “卖出（d）” 评级。Wall Street Zen 在周六的报告中将 Dynavax Technologies 的评级提升至 “强力买入”。最后，William Blair 在 12 月 24 日星期三的研究报告中将 Dynavax Technologies 的评级从 “跑赢大盘” 下调至 “持有”。两位股票研究分析师给予该股票买入评级，一位给予持有评级，两位给予卖出评级。根据 MarketBeat.com 的数据，该股票的共识评级为 “持有”，共识目标价为 24.33 美元。</p>
</div><p><strong>Read Our Latest Research Report on DVAX</strong></p>
<div class="lb-trans"><p><strong>阅读我们关于 DVAX 的最新研究报告</strong></p>
</div><h2>About Dynavax Technologies</h2>
<div class="lb-trans"><h2>关于 Dynavax Technologies</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Dynavax Technologies Corporation is a biopharmaceutical company focused on the development and commercialization of novel vaccines and immunotherapies. Headquartered in Emeryville, California, the company specializes in leveraging its proprietary Toll-like receptor (TLR) agonist platform to enhance immune responses. Its lead product, HEPLISAV-B, is a two-dose hepatitis B vaccine approved by the U.S. Food and Drug Administration that incorporates the CpG 1018 adjuvant to stimulate a rapid and robust antibody response in adults.</p>
<div class="lb-trans"><p>Dynavax Technologies Corporation 是一家生物制药公司，专注于新型疫苗和免疫疗法的开发和商业化。公司总部位于加利福尼亚州埃默里维尔，专注于利用其专有的类 Toll 样受体（TLR）激动剂平台来增强免疫反应。其主要产品 HEPLISAV-B 是一种两剂量的乙型肝炎疫苗，已获得美国食品和药物管理局的批准，结合了 CpG 1018 佐剂，以刺激成人快速而强烈的抗体反应。</p>
</div><p>Founded in 1993, Dynavax has built a pipeline that extends beyond hepatitis B to include candidates targeting seasonal influenza, respiratory syncytial virus (RSV) and emerging infectious diseases.</p>
<div class="lb-trans"><p>Dynavax 成立于 1993 年，已建立起一个超越乙型肝炎的产品管道，包括针对季节性流感、呼吸道合胞病毒（RSV）和新兴传染病的候选药物。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>特色文章</h2>
</div><ul>
<li>Five stocks we like better than Dynavax Technologies</li>
<li>This $15 Stock Could Go Down as the #1 Stock of 2026</li>
<li>I'm 70 With $1.5M: Would Converting $120K a Year to a Roth Be Smart or a Costly Mistake? (Ask An Advisor)</li>
<li>URGENT: Sell this stock immediately</li>
<li>They just tried to kill gold</li>
<li>Your Bank Account Is No Longer Safe</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 Dynavax Technologies</li>
<li>这只 15 美元的股票可能会成为 2026 年的第一只股票</li>
<li>我 70 岁，拥有 150 万美元：将每年 12 万美元转换为罗斯 IRA 是否明智，还是代价高昂的错误？（咨询顾问）</li>
<li>紧急：立即出售这只股票</li>
<li>他们刚刚试图打击黄金</li>
<li>你的银行账户不再安全</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding DVAX?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Dynavax Technologies Corporation (NASDAQ:DVAX - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他对冲基金持有的 DVAX 吗？</strong> 访问 HoldingsChannel.com，获取 Dynavax Technologies Corporation（纳斯达克代码：DVAX - 免费报告）的最新 13F 备案和内部交易信息。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RFZBWA" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=DVAX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻警报由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Dynavax Technologies Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Dynavax Technologies 吗？</h2>
</div><p>Before you consider Dynavax Technologies, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Dynavax Technologies 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Dynavax Technologies wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而 Dynavax Technologies 并不在名单上。</p>
</div><p>While Dynavax Technologies currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Dynavax Technologies 目前在分析师中获得了持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

信安金融集团降低了德纳维制药公司 $DVAX 的股票头寸